/ Eli Lilly
/ Market Analysis
Why Is Novo Nordisk Stock Down 13% Premarket? Trial Fails to Match Eli Lilly
Novo Nordisk stock plunged over 13% in premarket trading after its experimental obesity drug CagriSema failed to prove non-inferiority to Eli Lilly's ...
February 23, 2026
Why Is Eli Lilly (LLY) Stock Up Premarket? $2.4B Biotech Acquisition
Eli Lilly shares rose in premarket trading after the company announced a $2.4 billion deal to acquire Orna Therapeutics.
February 09, 2026
Why are Verve Therapeutics Shares Skyrocketing in Premarket Trading Today?
Eli Lilly is reportedly close to acquiring gene editing partner Verve Therapeutics for up to $1.3 billion.
June 17, 2025
Eli Lilly’s Stock Tumbles as Firm Cuts EPS Guidance Despite Strong Q1
Eli Lilly's stock dropped over 7% after announcing a lowered profit forecast, despite exceeding Q1 expectations.
May 01, 2025
LLY Stock Rebounds Amid AI-Driven ALS Research Breakthroughs
Verge Genomics and Eli Lilly have made significant progress in their collaboration to develop ALS treatments, identifying two promising drug targets using AI technology.
November 20, 2024More from The Tokenist / Eli Lilly
LLY vs NVO: Which One is Likely to Become a $1T Company First
February 08, 2024
Pfizer’s Stock is Down 44% YTD as Woes Continue
December 01, 2023
Back to 
